Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum
about
Artemisinin and a Series of Novel Endoperoxide Antimalarials Exert Early Effects on Digestive Vacuole MorphologyPurified E255L Mutant SERCA1a and Purified PfATP6 Are Sensitive to SERCA-type Inhibitors but Insensitive to ArtemisininsArtemisinin Action and Resistance in Plasmodium falciparumActivity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assayHemozoin and antimalarial drug discoveryPfPI3K, a phosphatidylinositol-3 kinase from Plasmodium falciparum, is exported to the host erythrocyte and is involved in hemoglobin traffickingThe malarial parasite Plasmodium falciparum imports the human protein peroxiredoxin 2 for peroxide detoxification.The Plasmodium protein network diverges from those of other eukaryotes.Artemisone effective against murine cerebral malariaThe antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release.Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion.PfMDR2 and PfMDR5 are dispensable for Plasmodium falciparum asexual parasite multiplication but change in vitro susceptibility to anti-malarial drugs.Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridineAmino acid efflux by asexual blood-stage Plasmodium falciparum and its utility in interrogating the kinetics of hemoglobin endocytosis and catabolism in vivoCurrent opinion on an emergence of drug resistant strains of Plasmodium falciparum through genetic alterations.Antimalarial drug therapy: the role of parasite biology and drug resistance.Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium.Artemisinin resistance in rodent malaria--mutation in the AP2 adaptor μ-chain suggests involvement of endocytosis and membrane protein trafficking.Current therapies and future possibilities for drug development against liver-stage malaria.Psychological stress exacerbates primary vaginal herpes simplex virus type 1 (HSV-1) infection by impairing both innate and adaptive immune responses.Psychological stress impairs the local CD8+ T cell response to mucosal HSV-1 infection and allows for increased pathogenicity via a glucocorticoid receptor-mediated mechanism.A new model for hemoglobin ingestion and transport by the human malaria parasite Plasmodium falciparum.Dual-functioning antimalarials that inhibit the chloroquine-resistance transporter.Autophagy in Plasmodium, a multifunctional pathway?Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparumKinetics of beta-haematin formation from suspensions of haematin in aqueous benzoic acid.Mefloquine induces ROS mediated programmed cell death in malaria parasite: Plasmodium.
P2860
Q22061805-26B95C86-499C-4BC0-A112-E2179C0C99B1Q22061846-DC352BFA-86DC-46B4-AC3C-752D27183B12Q28276294-C64EA496-BDE3-4F09-8C9A-4215AC32D507Q28482292-27E20B11-353E-4FCD-A042-6F4936724FD6Q28828253-98AAF5C4-CEDA-4D93-AFDB-A46FCB60FD5DQ30043721-49D4BA60-071E-423C-A176-8F14C391EBC3Q30489505-C70DEF54-6C5C-40D0-A85A-4DC07EDDA3C1Q33697242-DF6B624B-1B88-4EFD-9543-2CCAA06A0DCCQ34084173-2E569696-EC34-4C01-9CC6-230CF3BB2316Q34721762-94BAE21D-5438-4E5E-8BAA-BFC7E96F615EQ35105092-57D74156-6604-4186-AD47-3E085E759FD2Q35149404-CF657200-BE5A-47B2-A835-43BCE89E80C0Q35573542-8BC7564D-E253-459B-8BC7-A3E5B959F4EFQ36055139-3D1C8AF2-A408-4B3B-8624-D923577B42E5Q36469382-145C05E9-6FD8-4C61-BDC3-12B23982A3B8Q36652599-BC4D0883-2280-444D-B069-787DFE6D9098Q36788489-E8904417-FD35-4B8F-A608-A0779BFAF4C9Q36849304-A6CE2271-3A81-4FFB-811C-840B4776F019Q36951722-1F8790F5-5579-4C64-9F5A-975DC0E8CC0BQ37041253-56017A51-F57E-4FF6-A510-DC1CC05A8639Q37041318-BF170FD9-47BE-449E-B500-235CF2566188Q37409282-E86983B8-8571-400F-B2B0-6E83473E0D19Q38093645-0A515731-8AFF-4982-B1F7-E547B1FFD3F0Q38201049-2C546CA4-1714-4C84-B164-0366AF4E14DFQ39947285-FD8CF813-3378-42A8-B319-78CFDDFCAEB3Q41827568-5D9942DD-950D-49CA-A84E-2D2A48BDCDA3Q41910682-92DC6E7B-EC2B-49BB-A769-312FD3E13A45Q46160167-2D2B155E-1119-435E-BE9D-EDD1C41DAF87Q46525450-CAA566FE-67D3-4A16-B8B9-2F05D4C9F2A9
P2860
Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum
@en
type
label
Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum
@en
prefLabel
Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum
@en
P2093
P2860
P921
P1476
Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum
@en
P2093
Brandon W Weber
Donelly A van Schalkwyk
Joanne Egan
Sandra A Meredith
Ursula I M Wiehart
P2860
P304
P356
10.1128/AAC.48.7.2370-2378.2004
P407
P577
2004-07-01T00:00:00Z